Please use this identifier to cite or link to this item:
https://hdl.handle.net/2440/80360
Citations | ||
Scopus | Web of Science® | Altmetric |
---|---|---|
?
|
?
|
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Marathe, C. | - |
dc.contributor.author | Rayner, C. | - |
dc.contributor.author | Jones, K. | - |
dc.contributor.author | Horowitz, M. | - |
dc.date.issued | 2013 | - |
dc.identifier.citation | Peptides, 2013; 44:75-86 | - |
dc.identifier.issn | 0196-9781 | - |
dc.identifier.issn | 1873-5169 | - |
dc.identifier.uri | http://hdl.handle.net/2440/80360 | - |
dc.description.abstract | The gut derived peptides, glucagon-like peptides 1 and 2 (GLP-1 and GLP-2), are secreted following nutrient ingestion. GLP-1 and another gut peptide, glucose-dependent insulinotropic polypeptide (GIP) are collectively referred to as 'incretin' hormones, and play an important role in glucose homeostasis. Incretin secretion shares a complex interdependent relationship with both postprandial glycemia and the rate of gastric emptying. GLP-1 based therapies are now well established in the management of type 2 diabetes, while recent literature has suggested potential applications to treat obesity and protect against cardiovascular and neurological disease. The mechanism of action of GLP-2 is not well understood, but it shows promise as an intestinotropic agent. | - |
dc.description.statementofresponsibility | Chinmay S. Marathe, Christopher K. Rayner, Karen L. Jones, Michael Horowitz | - |
dc.language.iso | en | - |
dc.publisher | Elsevier Science Inc | - |
dc.rights | © 2013 Elsevier Inc. All rights reserved. | - |
dc.source.uri | http://www.sciencedirect.com/science/article/pii/S0196978113000338 | - |
dc.subject | Pancreas | - |
dc.subject | Animals | - |
dc.subject | Humans | - |
dc.subject | Diabetes Mellitus, Type 2 | - |
dc.subject | Blood Glucose | - |
dc.subject | Receptors, Glucagon | - |
dc.subject | Gastric Emptying | - |
dc.subject | Postprandial Period | - |
dc.subject | Glucagon-Like Peptide 1 | - |
dc.subject | Glucagon-Like Peptide 2 | - |
dc.subject | Clinical Trials as Topic | - |
dc.subject | Incretins | - |
dc.title | Glucagon-like peptides 1 and 2 in health and disease: A review | - |
dc.type | Journal article | - |
dc.identifier.doi | 10.1016/j.peptides.2013.01.014 | - |
pubs.publication-status | Published | - |
dc.identifier.orcid | Rayner, C. [0000-0002-5527-256X] | - |
dc.identifier.orcid | Jones, K. [0000-0002-1155-5816] | - |
dc.identifier.orcid | Horowitz, M. [0000-0002-0942-0306] | - |
Appears in Collections: | Aurora harvest 4 Medicine publications |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.